<?xml version="1.0" encoding="UTF-8"?>
<p>The anti-malarial drugs hydroxychloroquine and chloroquine have demonstrated antiviral activity SARS-CoV-2 
 <italic>in vitro</italic> (
 <xref rid="ref22" ref-type="bibr">22</xref>). A Chinese study found that chloroquine will reduce the symptom duration, exacerbation of pneumonia, including radiological improvement, and promotes virus-negative seroconversion with no side effects (
 <xref rid="ref23" ref-type="bibr">23</xref>). Because of the COVID-19 pandemic, the FDA has approved an emergency authorization for use of chloroquine and hydroxychloroquine (FDA: Emergency Use Authorization Information). Chloroquine is currently undergoing clinical trials for the treatment of COVID-19 (
 <xref rid="ref23" ref-type="bibr">23</xref>).
</p>
